To compare the safety and efficacy of totally implantable venous access ports via jugular and subclavian venous access in cancer patients.

Between January 2017 to December 2019, a total of 730 cancer patients received totally implantable venous access ports via jugular or subclavian venous access in our hospital were selected as the research subjects. They were divided into the internal jugular vein group and the subclavian vein group according to access. Complications were compared and analyzed between the two groups.

This study included a total of 730 patients, including 171 in the internal jugular vein group and 559 in the subclavian vein group. The incidence of catheter-related mechanical complications (including catheter rupture, catheter clamping, and catheter detachment) in the transjugular group was 0.58% (1/171), significantly lower than 4.65% (26/559) in the subclavian vein group, with a statistically significant difference (P < 0.05). There was no statistically significant difference in the incidence of thrombosis, infection, catheter displacement, port reversal, pneumothorax, and hemothorax between the two groups (P > 0.05).

Compared with the subclavian vein group, the internal jugular vein group had a lower incidence of catheter-related mechanical complications. Compared with subclavian vein, jugular vein access seems to bea better choice for totally implantable venous access ports implantation in cancer patients.